Accounts Receivable, after Allowance for Credit Loss, Current of CASI Pharmaceuticals, Inc. from 31 Dec 2021 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
CASI Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2021 to 31 Dec 2024.
  • CASI Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2024 was $15,345,000, a 61% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

CASI Pharmaceuticals, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $15,345,000 +$5,794,000 +61% 31 Dec 2024 20-F 31 Mar 2025 2024 FY
Q4 2023 $9,551,000 -$3,422,000 -26% 31 Dec 2023 20-F 31 Mar 2025 2024 FY
Q4 2022 $12,973,000 +$3,170,000 +32% 31 Dec 2022 20-F 28 Mar 2024 2023 FY
Q4 2021 $9,803,000 31 Dec 2021 20-F 26 Apr 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.